Eli Lilly & Co

Explore how Eli Lilly’s breakthrough obesity drug retatrutide and its expanding oncology lineup, set to debut at ASCO 2026, are positioning the company for long‑term growth and investor confidence.

Read how Eli Lilly’s 2026 earnings forecast, Zepbound/Foundayo gains, and a $2.25 B gene‑editing partnership could boost investor confidence amid GLP‑1 competition.

Eli Lilly’s Q1 earnings will reveal if Foundayo’s slow GLP‑1 adoption and its $7 billion Kelonia CAR‑T deal can sustain growth and diversify revenue in 2024.

Explore how Eli Lilly’s weight‑loss drugs navigate the CMS “bridge program” and delayed BALANCE pilot, plus EMA procurement trends, to secure Medicare revenue and long‑term growth.

Discover how Eli Lilly’s acquisition of Kelonia’s universal CAR‑T platform and launch of the oral GLP‑1 drug Foundayo combine oncology innovation with obesity treatment, driving growth and shareholder value.

AI‑driven Lilly‑Insilico deal promises faster, safer oral drugs & Phase 3b Taltz‑Zepbound hits psoriasis and metabolic targets, boosting Lilly’s therapeutic edge.

How Eli Lilly’s AI‑driven drug‑development boosts speed and investor appeal while keeping a steady, low‑volatility stock profile.

Explore Eli Lilly’s strategy to beat patent cliffs, grow with high‑margin oncology and neuroscience drugs, and use targeted M&A to drive future revenue.

Explore how Eli Lilly’s diversified portfolio and AI‑powered drug discovery boost its competitive edge, driving long‑term growth amid pharma’s evolving landscape.

How Eli Lilly battles Novo Nordisk’s price cuts: portfolio tweaks, pipeline pushes and global moves keep the pharma titan poised for tomorrow’s market shifts.